us in vitro diagnostic in cardiology and neurology market growth, ivd in cardiology and neurology market size, in vitro diagnostic market trends, in vitro diagnostic in cardiology and neurology market outlook, in vitro diagnostic ivd in cardiology and neurology market analysis, in vitro diagnostic ivd in cardiology and neurology industry outlook
How has the in vitro diagnostic (ivd) in cardiology and neurology market evolved, and where is it heading next?
The in vitro diagnostic (IVD) in cardiology and neurology market size has grown strongly in recent years. It will grow from $15.84 billion in 2024 to $17.27 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to rise in the prevalence of age-related cardiovascular and neurological disorders, rise in the aging population, growing emphasis on preventive healthcare and early disease detection, the increasing burden of cardiovascular diseases (CVDs) and neurological disorders, such as stroke and Alzheimer’s disease, rise in investments in healthcare infrastructure, and rise in supportive regulatory frameworks governing the approval and reimbursement of diagnostic tests.
The in vitro diagnostic (IVD) in cardiology and neurology market size is expected to see strong growth in the next few years. It will grow to $24.07 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to the shift towards personalized medicine in cardiology and neurology, increasing demand for rapid and on-site testing solutions in cardiology and neurology, expansion of telemedicine and remote consultation services, and rise in research initiatives. Major trends in the forecast period include emergence of liquid biopsy technologies, advancements in nanotechnology, adoption of remote monitoring devices, such as implantable cardiac monitors and brain-computer interfaces, use of multiplex biomarker panels, innovations in medical imaging modalities, such as MRI, CT, and PET scans, and development of companion diagnostics for cardiovascular and neurological drugs.
Get Your Free Sample of The Global In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp
Which major factors have contributed to the expansion of the in vitro diagnostic (ivd) in cardiology and neurology market?
The expansion of personalized medicine is expected to fuel the growth of the in vitro diagnostic (IVD) in cardiology and neurology market going forward. Personalized medicine refers to a medical approach that tailors healthcare decisions, practices, interventions, and treatments to individual characteristics of each patient. Personalized medicine is expanding due to advancements in genomics, increased understanding of disease mechanisms, patient demand for tailored treatments, and regulatory support, among other factors. In vitro diagnostic (IVD) tests in cardiology and neurology facilitate personalized medicine by providing crucial information about an individual’s genetic makeup and disease status, guiding tailored treatment plans for improved efficacy and reduced risks. For instance, according to the Personalized Medicine Coalition, a US-based professional membership organization, in 2022, the approval of 12 new personalized medicines represented approximately 34% of all newly approved therapies, indicating a substantial increase from previous years. Therefore, the increasing number of personalized medicines is driving the growth of the in vitro diagnostic (IVD) in cardiology and neurology market.
How is the in vitro diagnostic (ivd) in cardiology and neurology market segmented?
The in vitro diagnostic (IVD) in cardiology and neurology market covered in this report is segmented –
1) By Product Type: Instruments, Reagents And Consumables, Software And Services
2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies
3) By End-User: Hospitals, Clinical Laboratories, Other End-Users
Subsegments:
1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices, Electrophysiology Devices
2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables
3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services
Order your report now for swift delivery
Who are the top competitors in the in vitro diagnostic (ivd) in cardiology and neurology market?
Major companies operating in the in vitro diagnostic (IVD) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience
Which key trends are expected to influence the in vitro diagnostic (ivd) in cardiology and neurology market in the coming years?
Major companies operating in the in vitro diagnostic (IVD) in cardiology and neurology market are developing AI-enabled integrated epigenetic engines for early disease detection and risk assessment. AI-enabled integrated epigenetic engines leverage machine-learning models and advanced biomarker analysis techniques to enhance sensitivity and accuracy in diagnosing and monitoring cardiovascular diseases, addressing critical drivers of disease progression. For instance, in February 2023, Cardio Diagnostics Holdings Inc., a US-based biotechnology company, launched PrecisionCHD, an AI-based blood test, designed for the early detection of coronary heart disease (CHD). Utilizing the company’s integrated epigenetic-genetic engine, this test evaluates CHD risk and aims to prevent and detect the most common form of cardiovascular disease. The new test combines epigenetic and genetic biomarkers with machine-learning algorithms, offering over 75% sensitivity for both men and women. It links a patient’s biomarker profile to modifiable risk factors, major contributors to CHD, like smoking, diabetes, hypertension, and high cholesterol. PrecisionCHD represents a non-invasive alternative to exercise stress tests or angiograms, with blood samples drawn in-office or at home.
Which regional trends are influencing the in vitro diagnostic (ivd) in cardiology and neurology market, and which area dominates the industry?
North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (IVD) in cardiology and neurology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Report 2025 Offer?
The in vitro diagnostic (ivd) in cardiology and neurology market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
In vitro diagnostic (IVD) in cardiology and neurology refers to medical tests performed on samples such as blood, urine, or tissue outside the body to diagnose various cardiovascular and neurological conditions. These tests play a crucial role in early detection, monitoring, and treatment decisions for diseases such as heart disease, stroke, Alzheimer’s disease, and others. It also provides timely diagnostic information, guiding patient management, and improving outcomes in cardiology and neurology.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15829
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
